Has John Abesamis received payments from drug or device companies?

Yes. Drug and device makers reported $6,171 in general payments to John Abesamis across 213 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Abesamis did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Abesamis come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Abesamis

Primary Care · Honolulu, HINPI 1518721802

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 213 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AstraZeneca at 29.2% of the total. Among primary care clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,171in general payments, 2019–2025

Across 213 payments — averaging $28.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$2K
Novo Nordisk$795
AbbVie$578
Bayer$472
GSK$367
Abbott$302
plus $2K from 13 others

What the payments were for

Food & beverage$6,171100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	49	$1,802
Novo Nordisk	28	$795
AbbVie	26	$578
Bayer	17	$472
GSK	13	$367
Abbott	6	$302
ANI Pharmaceuticals, Inc.	9	$299
Kowa Pharmaceuticals America, Inc.	15	$288
Amgen	18	$282
Gilead	7	$265
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	4	$171
Boehringer Ingelheim	5	$146
Insulet Corporation	4	$90
Agios Pharmaceuticals, Inc.	3	$84
Exact Sciences	3	$82
Lilly USA, LLC	2	$55
Esperion Therapeutics, Inc.	2	$36
Merck	1	$31
Otsuka America Pharmaceutical, Inc.	1	$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,171 in reported general payments places this provider in the 90th percentile of 24 primary care providers in Hawaii.

See all primary care providers in Hawaii →

Other primary care in Honolulu

Czamira NordstromHonolulu$10K
Hye Won KangHonolulu$9K
Rebecca Fojas-CalimpongHonolulu$6K
Donita ValdezHonolulu$2K
Anthone JeonHonolulu$693
Gayane BejanyanHonolulu$55
Brittney WhalenKaneohe$5K
Rizelle TalonWaipahu$5K
Johanna AuKapolei$5K
Michelle OjiriHilo$1K

See the full list for Hawaii →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →